June 16, 2019

Fakih IVF Fertility Center extends its services to Emirates...

Fakih IVF Dubai recently partnered with Emirates Specialty Hospital in Dubai Healthcare City to provide assisted reproductive treatment to patients battling infertility.

The partnership allows Fakih IVF Fertility"...

Read More >
June 11, 2019

New Analysis Shows Sleep Apnea More Common in Americas than...

ResMed (NYSE: RMD) (ASX: RMD) revealed roughly 170 million people across North and South America have sleep apnea, according to a study it presented at the annual SLEEP meeting hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society.

The"...

Read More >
June 11, 2019

Boehringer Ingelheim and University of Dundee Highlight...

  • Boehringer Ingelheim and University of Dundee achieve milestone in collaboration aimed at developing novel protein degradation medicines
  • Results published in Nature Chemical Biology showcase the use of the broadly applicable structure-based PROTAC design approach to discover highly potent and selective drug candidates
  • The first PROTAC...

    Read More >
June 11, 2019

New post-hoc analysis shows consistent cardiorenal risk...

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a new post-hoc analysis of data from the EMPA-REG OUTCOME® trial. These results indicated that the effect of empagliflozin on reducing cardiovascular and renal risk was consistent between a sub-group"...

Read More >
June 11, 2019

Full data from CAROLINA® outcome trial support...

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiovascular risk.1 The findings were"...

Read More >
June 9, 2019

Microsure’s MUSA Microsurgery Robot Receives CE-mark...

(AETOS Wire)-- MUSA is the world’s first surgical robot for open microsurgery. This robotic assistant is clinically and commercially available after the medical device CE-mark was issued by notified body DEKRA recently. Microsure’s MUSA"...

Read More >
June 9, 2019

Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in...

(AETOS Wire) -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) today announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis did not meet the first of two primary endpoints. Treatment with NINLAROTM (ixazomib) in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic response compared to physician’s choice of standard of care regimens. As a result of this analysis, Takeda has decided to discontinue the trial. “While we are disappointed with this outcome, we aim to maximize our learnings from this......

Read More >
June 7, 2019

Takeda Presents Results from Lung Portfolio Including Phase...

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that new data for TAK-788 will be presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 3 at 10:12 a.m. CT in Chicago. Results from a Phase 1/2 first-in-human, open-label, multicenter study showed TAK-788 yielded a median progression-free survival (PFS) of 7.3 months and a confirmed objective response rate (ORR) of 43% in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations. These findings......

Read More >
June 7, 2019

Joe Kiani Named Honorary Academic by Mexican Academy of...

The Mexican Academy of Surgery (Academia Mexicana de Cirugía A.C.), an advisory body of the Mexican Federal Government, named Joe Kiani an Honorary Academic of the organization. Kiani is the founder of Masimo,"...

Read More >
June 6, 2019

US FDA and EMA Accept Applications for Ozanimod for the...

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for ozanimod for the treatment of people with relapsing forms of multiple sclerosis (RMS) in the United States. The European Medicines Agency"...

Read More >

Top News



Forex News Headline

Found articles: - Pages